EUVIMEDEUVIMED entdecken
Fallbericht

A case of destination therapy for post-fulminant myocarditis with myelodysplastic syndrome

Makiko Nakamura, Teruhiko Imamura, Yuki Hida, Toshihide Izumida, Masaki Nakagaito, Saori Nagura, Toshio Doi, Kazuaki Fukahara, Koichiro Kinugawa

Journal of Artificial Organs · 2025

DOI: 10.1007/s10047-024-01455-x ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Artificial Organs, 2025. Verfasst von Makiko Nakamura und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan. Hauptthemen laut MEDLINE: Myocarditis, Myelodysplastic Syndromes, Heart-Assist Devices, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We encountered a 64-year-old woman who experienced fulminant myocarditis and underwent treatment with veno-arterial extracorporeal membrane oxygenation and Impella CP support. Subsequently, she underwent a device upgrade to Impella 5.5 and received continuous hemodiafiltration for 3 months. During mechanical circulatory support, she developed refractory anemia and thrombocytopenia, leading to a diagnosis of myelodysplastic syndrome. Following the removal of the devices, she no longer required blood transfusions. She received HeartMate 3 left ventricular assist device implantation as a destination therapy indication despite the presence of myelodysplastic syndrome. She was successfully managed by aspirin-free antithrombotic therapy without any hemocompatibility-related adverse events for 4 months after index discharge on foot. We present a patient with a unique and rare presentation, wherein HeartMate 3 was implanted and successfully managed without aspirin to prevent bleeding complications associated with myelodysplastic syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisMyelodysplastic SyndromesHeart-Assist DevicesThrombosisShock, CardiogenicHumansFemaleExtracorporeal Membrane OxygenationFibrinolytic AgentsHemorrhageEchocardiographyTreatment Outcome

Stichwörter der Autor:innen

Cardiogenic shockHemocompatibilityLeft ventricular assist deviceMDS

Substanzen

Fibrinolytic Agents

Autor:innen und Institutionen

  • The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan.
  • The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan. teimamu@med.u-toyama.ac.jp.
  • Department of Cardiovascular Surgery, University of Toyama, Toyama, Toyama, Japan.

Zitieren

APA

Nakamura, M., Imamura, T., Hida, Y., Izumida, T., Nakagaito, M., Nagura, S., Doi, T., Fukahara, K., & Kinugawa, K. (2025). A case of destination therapy for post-fulminant myocarditis with myelodysplastic syndrome. Journal of Artificial Organs. https://doi.org/10.1007/s10047-024-01455-x

Vancouver

Nakamura M, Imamura T, Hida Y, Izumida T, Nakagaito M, Nagura S, et al. A case of destination therapy for post-fulminant myocarditis with myelodysplastic syndrome. Journal of Artificial Organs. 2025. doi:10.1007/s10047-024-01455-x

BibTeX
@article{Nakamura2025,
  author = {Nakamura, Makiko and Imamura, Teruhiko and Hida, Yuki and Izumida, Toshihide and Nakagaito, Masaki and Nagura, Saori and Doi, Toshio and Fukahara, Kazuaki and Kinugawa, Koichiro},
  title = {A case of destination therapy for post-fulminant myocarditis with myelodysplastic syndrome},
  journal = {Journal of Artificial Organs},
  year = {2025},
  doi = {10.1007/s10047-024-01455-x}
}
Kostenlos starten →